Fujioka, Ken, O'Neil, Patrick M, Davies, Melanie, Greenway, Frank, Lau, David CW, Claudius, Birgitte, Skjoth, Trine Vang, Jensen, Christine Bjorn and Wilding, John PH ORCID: 0000-0003-2839-8404
(2016)
Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers.
OBESITY, 24 (11).
pp. 2278-2288.
Text
Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers.pdf - Published version Download (595kB) |
Abstract
<h4>Objective</h4>To identify an early response criterion for predicting ≥5% weight loss with liraglutide 3.0 mg at week 56 and to compare efficacy outcomes in early responders (ERs) and early nonresponders (ENRs).<h4>Methods</h4>Using pooled data from the SCALE Obesity and Prediabetes and SCALE Diabetes trials, weight loss of ≥4% at 16 weeks best predicted ≥5% weight loss after 56 weeks. Weight loss and changes in cardiometabolic risk factors and health-related quality of life were evaluated in ERs (≥4% weight loss at week 16) and ENRs (<4% weight loss at week 16) completing 56 weeks' treatment.<h4>Results</h4>Proportions of ERs/ENRs to liraglutide 3.0 mg were 77.3%/22.7% (individuals without type 2 diabetes, T2D) and 62.7%/37.3% (those with T2D). Greater mean weight loss was observed in ERs versus ENRs: 10.8% versus 3.0% (without T2D) and 8.5% versus 3.1% (T2D). In both trials, greater proportions of ERs versus ENRs achieved ≥5%, >10%, and >15% weight loss at week 56 with liraglutide 3.0 mg. Greater improvements in cardiometabolic risk factors and health-related quality of life scores were observed in ERs versus ENRs.<h4>Conclusions</h4>The early response criterion was clinically useful to identify individuals who would achieve clinically meaningful weight loss at 56 weeks.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | Respiratory System, Cardiovascular System, Humans, Prediabetic State, Obesity, Body Weight, Weight Loss, Anti-Obesity Agents, Body Mass Index, Treatment Outcome, Exercise, Endpoint Determination, Risk Factors, Double-Blind Method, Dose-Response Relationship, Drug, Quality of Life, Adult, Middle Aged, Female, Male, Biomarkers, Liraglutide |
Depositing User: | Symplectic Admin |
Date Deposited: | 01 Feb 2017 09:42 |
Last Modified: | 19 Jan 2023 07:19 |
DOI: | 10.1002/oby.21629 |
Related URLs: | |
URI: | https://livrepository.liverpool.ac.uk/id/eprint/3005492 |